Stay updated on Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page.

Latest updates to the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page
- ChecktodayChange DetectedThe site footer revision changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check28 days agoChange DetectedAn NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears, and the site revision updates from v3.7.1 to v3.7.2.SummaryDifference0.6%

- Check42 days agoChange DetectedThe site footer revision indicator changed from v3.7.0 to v3.7.1, reflecting an updated website release version.SummaryDifference0.1%

- Check63 days agoChange DetectedThe history now shows a new revision tag upgrading from v3.6.6 to v3.7.0, representing a new version entry for the study record history.SummaryDifference0.1%

- Check77 days agoChange DetectedA new Revision: v3.6.6 is added to the history and the previous Revision: v3.6.5 is removed. This reflects a minor platform/UI update to the record history display rather than any change to the study data.SummaryDifference0.1%

Stay in the know with updates to Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy Selinexor Pembrolizumab Combo in Melanoma Clinical Trial page.